Biokin Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biokin Pharmaceutical - overview
Established
1996
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Sichuan, China, and founded in 1996, Biokin Pharmaceutical operates as a biopharmaceutical developer focusing on pharmaceutical research and development, production, and marketing, with two new drug research and development centers, an antibody and ADC drug production enterprise, a chemical intermediate production enterprise, a chemical API production enterprise, two chemical preparation production enterprises and two marketing companies. The founder, Yi Zhu, graduated from Sichuan University and served as a lecturer at the West China University of Medical Sciences. The company's products can be categorized into pediatric drugs, cardiovascular drugs, anesthesia/critical care drugs, and chronic disease drugs. It has a full range of drug research and development capabilities, including small-molecule chemical drugs, large-molecule biological drugs, and ADC drugs.
Current Investors
Ronseal Investment Management, Xinjiang Xinxi Equity Investment Partnership
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.baili-pharm.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Biokin Pharmaceutical - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue (USD) | 1,206,623,639 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | 68,041,200 | - | - | - |
| Operating Income (USD) | 11,771,462.5 | - | - | - |
| Operating Margin | 1.0% | - | - | - |
| % EBITDA Margin | 5.6% | - | - | - |
| NET Income (USD) | 7,742,254.8 | - | - | - |
| % Net Margin | 0.6% | - | - | - |
Biokin Pharmaceutical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Biokin Pharmaceutical | - | ||||||||
| Buyout | Completed | Biokin Pharmaceutical | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.